AIMS: To demonstrate non-inferiority of ranibizumab treat-and-extend (T&E) with/without laser to ranibizumab pro re nata (PRN) for best-corrected visual acuity (BCVA) in patients with diabetic macular oedema (DMO). METHODS: A 24-month single-masked study with patients randomised 1:1:1 to T&E+laser (n=121), T&E (n=128) or PRN (control; n=123). All patients received monthly injections until BCVA stabilisation. The investigator decided on re-treatment in the PRN and treatment-interval adaptations in the T&E groups based on loss of BCVA stability due to DMO activity. Likewise, laser treatment was at investigator's discretion. Collectively, these features reflect a real-life scenario. Endpoints included mean average change in BCVA from baseline to months 1-12 (primary), mean BCVA change from baseline to months 12 and 24, treatment exposure and safety profile. RESULTS: Both T&E regimens were non-inferior to PRN based on mean average BCVA change from baseline to months 1-12 (T&E+laser: +5.9 and T&E: +6.1 vs PRN: +6.2 letters; both p<0.0001). Mean BCVA change at month 24 was similar across groups (+8.3, +6.5 and +8.1 letters, respectively). The mean number of injections was 12.4 and 12.8 in the T&E+laser and T&E groups and 10.7 in the PRN group. The T&E regimens showed 46% reduction in the number of clinic visits. Over 70% of patients maintained their BCVA, with treatment intervals of ≥2 months over 24 months. Safety profile was consistent with that described in the product information. CONCLUSIONS: T&E is a feasible treatment option for patients with DMO, with a potential to reduce treatment burden. Slightly more injections were required versus PRN, likely due to the specifics of the T&E regimen applied here. TRIAL REGISTRATION NUMBER: NCT01171976.

AIBILI Coimbra Portugal Coimbra Hospital and University Centre Coimbra Portugal Faculty of Medicine University of Coimbra Coimbra Portugal

Centre d'Imagerie et Laser Paris France

Department of Ophthalmology University Hospital Hradec Králové Czech Republic

Department of Ophthalmology Vista Klinik Binningen Switzerland Kantonsspital Baselland Eye Clinic Liestal Switzerland University of Basel Basel Switzerland

Department of Ophthalmology Vista Klinik Binningen Switzerland University of Basel Basel Switzerland

Novartis Pharma AG Basel Switzerland

PTV Foundation University of Rome Tor Vergata Rome Italy

Royal Eye Hospital Manchester UK

Zobrazit více v PubMed

Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984;91:1–9. PubMed

Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012;366:1227–39. 10.1056/NEJMra1005073 PubMed DOI

Chen E, Looman M, Laouri M, et al. . Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010;26:1587–97. 10.1185/03007995.2010.482503 PubMed DOI

Mitchell P, Bandello F, Schmidt-Erfurth U, et al. . The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615–25. 10.1016/j.ophtha.2011.01.031 PubMed DOI

Lang GE, Berta A, Eldem BM, et al. . Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: Interim analysis of the RESTORE Extension Study. Ophthalmology 2013;120:2004–12. 10.1016/j.ophtha.2013.02.019 PubMed DOI

Schmidt-Erfurth U, Lang GE, Holz FG, et al. . Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE Extension study. Ophthalmology 2014;121:1045–53. 10.1016/j.ophtha.2013.11.041 PubMed DOI

Elman MJ, Bressler NM, Qin H, et al. , Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609–14. 10.1016/j.ophtha.2010.12.033 PubMed DOI PMC

Elman MJ, Qin H, Aiello LP, et al. , Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012;119:2312–18. 10.1016/j.ophtha.2012.08.022 PubMed DOI PMC

Elman MJ, Ayala A, Bressler NM, et al. . Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015;122:375–81. 10.1016/j.ophtha.2014.08.047 PubMed DOI PMC

Spaide RF. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007;143:679–80. 10.1016/j.ajo.2007.02.024 PubMed DOI

Gupta OP, Shienbaum G, Patel AH, et al. . A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134–40. 10.1016/j.ophtha.2010.02.032 PubMed DOI

Abedi F, Wickremasinghe S, Islam AF, et al. . Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina 2014;34:1531–8. 10.1097/IAE.0000000000000134 PubMed DOI

Rayess N, Houston SK III, Gupta OP, et al. . Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 2015;159:3–8. 10.1016/j.ajo.2014.09.011 PubMed DOI

Berg K, Pedersen TR, Sandvik L, et al. . Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015;122:146–52. 10.1016/j.ophtha.2014.07.041 PubMed DOI

Oubraham H, Cohen SY, Samimi S, et al. . Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011;31:26–30. 10.1097/IAE.0b013e3181de5609 PubMed DOI

Pearce I, Banerjee S, Burton BJ, et al. . Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. Ophthalmology 2015;122:1811–19. 10.1016/j.ophtha.2015.05.038 PubMed DOI

European Medicines Agency. Lucentis: EPAR-Product Information. EMEA/H/C/000715-IB/0032. Updated 20 July, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf (accessed 15 May 2015).

Bhagat N, Grigorian RA, Tutela A, et al. . Diabetic Macular Edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1–32. 10.1016/j.survophthal.2008.10.001 PubMed DOI

Bretz F, Maurer W, Brannath W, et al. . A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009;28:586–604. 10.1002/sim.3495 PubMed DOI

Toalster N, Russell M, Ng P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina 2013;33:1351–8. 10.1097/IAE.0b013e3182831265 PubMed DOI

Do DV, Nguyen QD, Khwaja AA, et al. , for the READ-2 Study Group. Ranibizumab for oedema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 2013;131:139–45. 10.1001/2013.jamaophthalmol.91 PubMed DOI

Klein R, Klein BE, Moss SE, et al. . The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464–74. PubMed

Mercer BN, Morais S, Cubbon RM, et al. . Diabetes mellitus and the heart. Int J Clin Pract 2012;66:640–7. 10.1111/j.1742-1241.2012.02924.x PubMed DOI

European Medicines Agency. Summary of Product Characteristics. Lucentis 10 mg/ml solution for injection. Novartis 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdfhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf (accessed 15 May 2015).

Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01171976